The Technical Analyst
Ionis Pharmaceuticals Inc [IONS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ionis Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.60% $41.59
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6 061.83 mill |
| EPS: | -2.56 |
| P/E: | -16.25 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 145.75 mill |
| Avg Daily Volume: | 1.078 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -16.25 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.76x |
| Company: PE -16.25 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-19.92 (-147.89%) $-61.51 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 40.36 - 42.82 ( +/- 2.96%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Baroldi Joseph | Sell | 10 838 | Restricted Stock Unit |
| 2024-04-15 | Baroldi Joseph | Buy | 10 838 | Common Stock |
| 2024-04-16 | Baroldi Joseph | Sell | 4 006 | Common Stock |
| 2024-04-15 | Birchler Brian | Buy | 1 875 | Common Stock |
| 2024-04-16 | Birchler Brian | Sell | 905 | Common Stock |
| INSIDER POWER |
|---|
| 45.60 |
| Last 100 transactions |
| Buy: 1 051 999 | Sell: 391 277 |
Forecast:
16:00 - $41.60
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $41.60
Forecast 2: 16:00 - $41.60
Forecast 3: 16:00 - $41.60
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $41.59 (-0.60% ) |
| Volume | 0.540 mill |
| Avg. Vol. | 1.078 mill |
| % of Avg. Vol | 50.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IONS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $50.06 | N/A | Active |
|---|
IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-25 07:00:00 - Press Release
Ionis Publishes 2023 Corporate Responsibility Report
Established new corporate responsibility strategic pillars and actionable goals received approval for two ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medicines to people with serious diseases carlsbad, calif. , april 25, 2024 /prnewswire/ -- ionis pharmaceuticals, inc. (nasdaq: ions), today published its 2023 corporate responsibility report: action for a healthier future.
2024-04-23 07:05:00 - Press Release
Ionis To Hold First Quarter 2024 Financial Results Webcast
Webcast scheduled for tuesday, may 7 at 11:30 a.m. eastern time carlsbad, calif.
2024-04-07 09:48:00 - Press Release
Ionis Presents Positive Results From Phase 3 Balance Study Of Olezarsen For Familial Chylomicronemia Syndrome
– olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – – results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the u.s. – – data presented today at acc 2024 and published in the new england journal of medicine – – ionis to host webcast on monday, april 8 at 10:00 am et – carlsbad, calif. , april 7, 2024 /prnewswire/ -- ionis pharmaceuticals, inc. (nasdaq: ions) today announced full results from the phase 3 balance study of ionis' lead independent investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (fcs).
2024-04-01 07:05:00 - Press Release
Ionis To Present At Upcoming Investor Conferences
Carlsbad, calif. , april 1, 2024 /prnewswire/ -- ionis pharmaceuticals, inc. (nasdaq: ions) today announced that management will participate in fireside chats at the following investor conferences: 23rd annual needham virtual healthcare conference on monday, april 8, 2024 2024 rbc capital markets global healthcare conference on tuesday, may 14, 2024 bofa securities health care conference 2024 on tuesday, may 14, 2024 45th annual goldman sachs global healthcare conference on wednesday, june 12, 2024 a live webcast of these presentations can be accessed on the investors & media section of the ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
2024-03-28 07:05:00 - Press Release
Ionis To Hold Olezarsen Phase 3 Data Webcast
Webcast scheduled for monday, april 8 at 10:00 a.m. eastern time carlsbad, calif.
Latest News
2024-04-23 07:05:00 - PRNewsWire
Ionis to hold first quarter 2024 financial results webcast
2024-04-01 07:05:00 - PRNewsWire
Ionis to present at upcoming investor conferences
CARLSBAD, Calif. , April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024 45th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 12, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
2024-03-28 07:05:00 - PRNewsWire
Ionis to hold olezarsen Phase 3 data webcast
2024-03-25 10:10:29 - Zacks Investment Research
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
2024-03-14 11:41:10 - Zacks Investment Research
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Ionis (IONS) reports positive phase II study results, which show that treatment with ION224 has the potential to improve MASH and prevent its progression to more severe stages.
2024-03-08 09:11:16 - MarketBeat
Are These 5 Undervalued Stocks Ready to Break Out?
Albemarle Corp. NYSE: ALB, Ionis Pharmaceuticals Inc. NASDAQ: IONS, Insulet Corp. NASDAQ: PODD, Hess Corp. NYSE: HES and Wynn Resorts Ltd. NASDAQ: WYNN are among undervalued stocks that beat analysts earnings views.
2024-02-28 07:05:00 - PRNewsWire
Ionis to present at upcoming investor conferences
CARLSBAD, Calif. , Feb. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events.
2024-02-22 11:30:23 - Zacks Investment Research
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
2024-02-21 10:31:26 - Zacks Investment Research
Ionis Pharmaceuticals (IONS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
2024-02-21 09:05:33 - Zacks Investment Research
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.37 per share a year ago.